News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Aug 17, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, 2020, at 10:00 a.m. ET
Corporate Highlights Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma Repurchased $1.0 million of common stock during the three-month span ended June 30, 2020 SWK...
- Aug 14, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, at 10:00 a.m. ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020,...
- Jun 29, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today its addition to the broad-market Russell 3000® Index, the Russell 2000® Index and the...
- Jun 23, 2020Presentation Scheduled for June 25, 2020, at 11:30 a.m., ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today that Chairman and CEO Winston Black will present via webcast at the Life Sciences...
- Jun 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 02, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 14, 2020Conference Call and Live Audio Webcast Scheduled for Friday, May 15, 2020, at 10:00 a.m. ET
Corporate Highlights Core specialty finance segment generated an 11.3% adjusted ROIC, and yielding assets increased to $179.2 million, a 15.7% increase in comparison to the quarter ended March 31,...
- May 04, 2020Accomplished Industry Executive Brings Extensive Business Development Experience and Deep Knowledge of Drug Delivery Technology to Enteris
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 30, 2020Transformative 2019 Underscored by Strong Finance Results and Enteris BioPharma Acquisition
Corporate Highlights Core specialty finance segment generated a 12.6% adjusted ROIC and yielding assets increased 4.8% year over year to $175.1 million Closed Enteris Biopharma acquisition SWK...
- Mar 26, 2020SWK Holdings Expects to Report Adjusted Earnings for Fourth Quarter and Year End 2019 of $4.3 to $4.7 million and $21.0 to $21.4 million, respectively
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today announced its preliminary revenue and...